首页 > 最新文献

Journal of Basic and Clinical Physiology and Pharmacology最新文献

英文 中文
Gasotransmitters do not prevent changes in transepithelial ion transport induced by hypoxia followed by reoxygenation. 气体递质不能阻止缺氧后复氧引起的经上皮离子转运的变化。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-23 eCollection Date: 2024-01-01 DOI: 10.1515/jbcpp-2023-0034
Rebecca Claßen, Martin Diener, Ervice Pouokam

Objectives: How gaseous signalling molecules affect ion transport processes contributing to the physiological functions of the gastrointestinal tract under hypoxic conditions still needs to be clarified. The objective of the present study was to characterize the impact of gaseous signalling molecules on parameters of colonic ion transport during a hypoxia/reoxygenation cycle and the remaining secretory capacity of the epithelium after such a cycle.

Methods: Short-circuit current (Isc) and tissue conductance (Gt) recordings in Ussing chamber experiments were performed on rat colon samples using CORM-2 (putative CO donor; 35 and 350 µM), sodium nitroprusside (NO donor; 100 µM), NaHS (fast H2S donor; 10 - 1,000 µM), GYY 4137 (slow H2S donor; 50 µM) and Angeli's salt (HNO donor; 100 µM) as donors for gasotransmitters. Inhibition of endogenous synthesis of H2S was operated by inhibitors of cystathionin-γ-lyase, i.e. dl-propargylglycine (1 mM) or β-cyano-l-alanine (5 mM), and the inhibitor of cystathionine-β-synthase, amino-oxyacetate (5 mM).

Results: The fast gasotransmitter donors NaHS, sodium nitroprusside and Angeli's salt, administered 5 min before the onset of hypoxia, induced an increase in Isc. The response to the subsequently applied hypoxia was characterized by a decrease in Isc, which tended to be reduced only in the presence of the lowest concentration of NaHS (10 µM) tested. Reoxygenation resulted in a slow increase in Isc, which was unaffected by all donors or inhibitors tested. The stable acetylcholine derivative carbachol (50 µM) was administered at the end of each hypoxia/reoxygenation cycle to test the secretory capacity of the epithelium. Pretreatment of the tissue with the putative CO donor CORM-2 suppressed the secretory response induced by carbachol. The same was observed when cystathionin-γ-lyase and cystathionin-γ-synthase were inhibited simultaneously. Under both conditions, Gt drastically increased suggesting an impaired tissue integrity.

Conclusions: The present results demonstrate that none of the exogenous gasotransmitter releasing drugs significantly ameliorated the changes in epithelial ion transport during the hypoxia/reoxygenation cycle ex vivo. In contrast, the putative CO donor CORM-2 exerted a toxic effect on the epithelium. The endogenous production of H2S, however, seems to have a protective effect on the mucosal integrity and the epithelial transport functions, which - when inhibited - leads to a loss of the secretory ability of the mucosa. This observation together with the trend for improvement observed with a low concentration of the H2S donor NaHS suggests a moderate protective role of low concentrations of H2S under hypoxic conditions.

目的:气体信号分子如何影响缺氧条件下有助于胃肠道生理功能的离子转运过程仍有待明确。本研究的目的是确定气体信号分子在缺氧/复氧循环期间对结肠离子转运参数的影响,以及在此循环后上皮细胞剩余分泌能力的特征:方法:使用 CORM-2(假定的 CO 供体;35 和 350 µM)、硝普钠(NO 供体;100 µM)、NaHS(快速 H2S 供体;10 - 1,000 µM)、GYY 4137(慢速 H2S 供体;50 µM)和安吉利盐(HNO 供体;100 µM)作为气体递质的供体,在乌星室实验中对大鼠结肠样本进行短路电流(Isc)和组织电导(Gt)记录。胱硫醚-γ-裂解酶抑制剂,即 dl-丙炔甘氨酸(1 毫摩尔)或 β-氰基-l-丙氨酸(5 毫摩尔),以及胱硫醚-β-合成酶抑制剂氨基氧乙酸(5 毫摩尔)抑制了 H2S 的内源性合成:结果:在缺氧开始前 5 分钟给予快速气体递质供体 NaHS、硝普钠和安吉利盐可诱导 Isc 增加。对随后的缺氧反应的特点是 Isc 下降,只有在测试的最低浓度 NaHS(10 µM)存在的情况下,Isc 才有下降的趋势。复氧后,Isc 缓慢增加,不受所有供体或抑制剂的影响。在每个缺氧/复氧周期结束时,给予稳定的乙酰胆碱衍生物卡巴胆碱(50 µM),以测试上皮细胞的分泌能力。用假定的 CO 供体 CORM-2 对组织进行预处理可抑制卡巴胆碱诱导的分泌反应。同时抑制胱硫醚-γ-赖氨酸酶和胱硫醚-γ-合成酶时也观察到同样的情况。在这两种情况下,Gt 都急剧增加,表明组织完整性受损:本研究结果表明,没有一种外源性气体递质释放药物能明显改善体内缺氧/复氧循环过程中上皮离子转运的变化。相反,假定的 CO 供体 CORM-2 对上皮细胞产生了毒性作用。然而,内源性 H2S 的产生似乎对粘膜的完整性和上皮细胞的转运功能具有保护作用,当这种作用受到抑制时,会导致粘膜分泌能力的丧失。这一观察结果以及低浓度 H2S 供体 NaHS 的改善趋势表明,低浓度 H2S 在缺氧条件下具有适度的保护作用。
{"title":"Gasotransmitters do not prevent changes in transepithelial ion transport induced by hypoxia followed by reoxygenation.","authors":"Rebecca Claßen, Martin Diener, Ervice Pouokam","doi":"10.1515/jbcpp-2023-0034","DOIUrl":"10.1515/jbcpp-2023-0034","url":null,"abstract":"<p><strong>Objectives: </strong>How gaseous signalling molecules affect ion transport processes contributing to the physiological functions of the gastrointestinal tract under hypoxic conditions still needs to be clarified. The objective of the present study was to characterize the impact of gaseous signalling molecules on parameters of colonic ion transport during a hypoxia/reoxygenation cycle and the remaining secretory capacity of the epithelium after such a cycle.</p><p><strong>Methods: </strong>Short-circuit current (I<sub>sc</sub>) and tissue conductance (G<sub>t</sub>) recordings in Ussing chamber experiments were performed on rat colon samples using CORM-2 (putative CO donor; 35 and 350 µM), sodium nitroprusside (NO donor; 100 µM), NaHS (fast H<sub>2</sub>S donor; 10 - 1,000 µM), GYY 4137 (slow H<sub>2</sub>S donor; 50 µM) and Angeli's salt (HNO donor; 100 µM) as donors for gasotransmitters. Inhibition of endogenous synthesis of H<sub>2</sub>S was operated by inhibitors of cystathionin-γ-lyase, i.e. dl-propargylglycine (1 mM) or β-cyano-l-alanine (5 mM), and the inhibitor of cystathionine-β-synthase, amino-oxyacetate (5 mM).</p><p><strong>Results: </strong>The fast gasotransmitter donors NaHS, sodium nitroprusside and Angeli's salt, administered 5 min before the onset of hypoxia, induced an increase in I<sub>sc</sub>. The response to the subsequently applied hypoxia was characterized by a decrease in I<sub>sc</sub>, which tended to be reduced only in the presence of the lowest concentration of NaHS (10 µM) tested. Reoxygenation resulted in a slow increase in I<sub>sc</sub>, which was unaffected by all donors or inhibitors tested. The stable acetylcholine derivative carbachol (50 µM) was administered at the end of each hypoxia/reoxygenation cycle to test the secretory capacity of the epithelium. Pretreatment of the tissue with the putative CO donor CORM-2 suppressed the secretory response induced by carbachol. The same was observed when cystathionin-γ-lyase and cystathionin-γ-synthase were inhibited simultaneously. Under both conditions, G<sub>t</sub> drastically increased suggesting an impaired tissue integrity.</p><p><strong>Conclusions: </strong>The present results demonstrate that none of the exogenous gasotransmitter releasing drugs significantly ameliorated the changes in epithelial ion transport during the hypoxia/reoxygenation cycle ex vivo. In contrast, the putative CO donor CORM-2 exerted a toxic effect on the epithelium. The endogenous production of H<sub>2</sub>S, however, seems to have a protective effect on the mucosal integrity and the epithelial transport functions, which - when inhibited - leads to a loss of the secretory ability of the mucosa. This observation together with the trend for improvement observed with a low concentration of the H<sub>2</sub>S donor NaHS suggests a moderate protective role of low concentrations of H<sub>2</sub>S under hypoxic conditions.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"61-70"},"PeriodicalIF":0.0,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139541714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antioxidant therapy for hepatic diseases: a double-edged sword. 肝病的抗氧化疗法:一把双刃剑。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-19 eCollection Date: 2024-01-01 DOI: 10.1515/jbcpp-2023-0156
Sayandeep K Das, Savitri M Nerune, Kusal K Das

Liver diseases are complex conditions, significantly influenced by oxidative stress. This comprehensive review assesses the therapeutic role of antioxidants like l-ascorbic acid and α tocopherol, beta-carotene, various minerals, and plant-based ingredients in mitigating oxidative stress-induced liver diseases. The manuscript delves into the critical influence of genetic and epigenetic factors on disease susceptibility, progression, and response to antioxidant therapy. While animal studies suggest antioxidant efficacy in liver disease treatment, human trials remain inconclusive, and caution is advised due to its possible potential pro-oxidant effects. Moreover, the interactions of antioxidants with other drugs necessitate careful consideration in the management of polypharmacy in liver disease patients. The review underscores the need for further research to establish the clinical benefits of antioxidants with understanding of possible antioxidant toxicities to elucidate the intricate interplay of genetic, epigenetic, and environmental factors in liver diseases. The aim is to foster a better understanding of the knowledge on hepatic disease management with judicial antioxidant therapies.

肝病是一种复杂的疾病,受氧化应激的影响很大。这篇综述评估了抗氧化剂(如抗坏血酸和α生育酚)、β-胡萝卜素、各种矿物质和植物成分在减轻氧化应激诱发的肝病方面的治疗作用。手稿深入探讨了遗传和表观遗传因素对疾病易感性、进展和抗氧化疗法反应的关键影响。虽然动物研究表明抗氧化剂对肝病治疗有疗效,但人体试验仍无定论,而且由于其可能具有潜在的促氧化作用,因此建议谨慎使用。此外,抗氧化剂与其他药物的相互作用也需要在肝病患者的多种药物治疗中仔细考虑。本综述强调了进一步研究的必要性,以确定抗氧化剂的临床益处,同时了解可能的抗氧化剂毒性,从而阐明肝病中遗传、表观遗传和环境因素之间错综复杂的相互作用。目的是促进人们更好地了解利用司法抗氧化疗法治疗肝病的知识。
{"title":"Antioxidant therapy for hepatic diseases: a double-edged sword.","authors":"Sayandeep K Das, Savitri M Nerune, Kusal K Das","doi":"10.1515/jbcpp-2023-0156","DOIUrl":"10.1515/jbcpp-2023-0156","url":null,"abstract":"<p><p>Liver diseases are complex conditions, significantly influenced by oxidative stress. This comprehensive review assesses the therapeutic role of antioxidants like l-ascorbic acid and α tocopherol, beta-carotene, various minerals, and plant-based ingredients in mitigating oxidative stress-induced liver diseases. The manuscript delves into the critical influence of genetic and epigenetic factors on disease susceptibility, progression, and response to antioxidant therapy. While animal studies suggest antioxidant efficacy in liver disease treatment, human trials remain inconclusive, and caution is advised due to its possible potential pro-oxidant effects. Moreover, the interactions of antioxidants with other drugs necessitate careful consideration in the management of polypharmacy in liver disease patients. The review underscores the need for further research to establish the clinical benefits of antioxidants with understanding of possible antioxidant toxicities to elucidate the intricate interplay of genetic, epigenetic, and environmental factors in liver diseases. The aim is to foster a better understanding of the knowledge on hepatic disease management with judicial antioxidant therapies.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"7-14"},"PeriodicalIF":0.0,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139484446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evidences and therapeutic advantages of donanemab in the treatment of early Alzheimer's disease. 多奈单抗治疗早期阿尔茨海默病的证据和治疗优势。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-12-06 eCollection Date: 2024-01-01 DOI: 10.1515/jbcpp-2023-0176
Ajay Kumar Shukla, Saurav Misra

The humanised monoclonal antibody donanemab is being developed to treat early onset Alzheimer's disease (AD). This drug targets N-truncated pyroglutamate amyloid-peptide at position 3 (N3pG), a modified form of deposited amyloid-peptide. The symptoms of Alzheimer's disease include gradual memory loss and other cognitive impairments. This disease is characterized by amyloid plaques, which are formed as a result of an accumulation of amyloid-(A-β) peptides. Despite granting donanemab breakthrough therapy designation in June 2021, the FDA rejected donanemab's accelerated approval application in January 2023, due to inadequate safety data. According to the baseline amyloid level, the time to achieve plaque clearance (amyloid plaque level <24.1 centiloids) varied. Patients with higher baseline levels were more likely to achieve amyloid clearance. The safety of the drug was demonstrated by amyloid-related imaging abnormalities (ARIA), which ranged from 26.1 to 30.5 % in the studies. Clinical trial results have shown that donanemab delays cognitive and functional deterioration in patients with mild to moderate AD. However, it is not yet known whether donenameb offers therapeutic benefits that can change and improve the clinical condition of AD patients. To achieve significant clinical benefits in AD patients with cognitive impairment, further studies may be needed to investigate the interaction between A-β plaque reduction and toxic tau levels.

目前正在开发人源化单克隆抗体 Donanemab,用于治疗早发性阿尔茨海默病(AD)。这种药物的靶点是位于第 3 位的 N-截短焦谷氨酸淀粉样肽(N3pG),这是一种经过修饰的淀粉样肽沉积形式。阿尔茨海默病的症状包括逐渐丧失记忆和其他认知障碍。这种疾病的特征是淀粉样蛋白斑块,它是淀粉样蛋白-(A-β)肽累积形成的结果。尽管美国食品和药物管理局于2021年6月授予多那尼单抗突破性疗法称号,但由于安全性数据不足,于2023年1月拒绝了多那尼单抗的加速审批申请。根据基线淀粉样蛋白水平,达到斑块清除的时间(淀粉样蛋白斑块水平
{"title":"Evidences and therapeutic advantages of donanemab in the treatment of early Alzheimer's disease.","authors":"Ajay Kumar Shukla, Saurav Misra","doi":"10.1515/jbcpp-2023-0176","DOIUrl":"10.1515/jbcpp-2023-0176","url":null,"abstract":"<p><p>The humanised monoclonal antibody donanemab is being developed to treat early onset Alzheimer's disease (AD). This drug targets N-truncated pyroglutamate amyloid-peptide at position 3 (N3pG), a modified form of deposited amyloid-peptide. The symptoms of Alzheimer's disease include gradual memory loss and other cognitive impairments. This disease is characterized by amyloid plaques, which are formed as a result of an accumulation of amyloid-(A-β) peptides. Despite granting donanemab breakthrough therapy designation in June 2021, the FDA rejected donanemab's accelerated approval application in January 2023, due to inadequate safety data. According to the baseline amyloid level, the time to achieve plaque clearance (amyloid plaque level <24.1 centiloids) varied. Patients with higher baseline levels were more likely to achieve amyloid clearance. The safety of the drug was demonstrated by amyloid-related imaging abnormalities (ARIA), which ranged from 26.1 to 30.5 % in the studies. Clinical trial results have shown that donanemab delays cognitive and functional deterioration in patients with mild to moderate AD. However, it is not yet known whether donenameb offers therapeutic benefits that can change and improve the clinical condition of AD patients. To achieve significant clinical benefits in AD patients with cognitive impairment, further studies may be needed to investigate the interaction between A-β plaque reduction and toxic tau levels.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"25-29"},"PeriodicalIF":0.0,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138487631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus? 小分子GLP-1激动剂能否成为治疗2型糖尿病的下一个一线药物?
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-12-05 eCollection Date: 2024-01-01 DOI: 10.1515/jbcpp-2023-0234
Rajmohan Seetharaman, Swarnima Pandit
{"title":"Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus?","authors":"Rajmohan Seetharaman, Swarnima Pandit","doi":"10.1515/jbcpp-2023-0234","DOIUrl":"10.1515/jbcpp-2023-0234","url":null,"abstract":"","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138477808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preoperative CT diagnosis of perforated Meckel's diverticulitis in a young patient: a case report. 年轻穿孔性梅克尔憩室炎的术前CT诊断1例。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-11-29 eCollection Date: 2024-01-01 DOI: 10.1515/jbcpp-2023-0237
Michele Gambardella, Michele Smaldone, Francesco Iazzetta, Maria Carmela Corbisiero, Gennaro Graviero, Giuseppe Morelli Coppola

Objectives: Meckel's diverticulum (MD) is a common asymptomatic congenital intestinal anomaly. Clinical manifestations of MD can occur in about 4 % of cases by the presentation of its complications, generally intestinal occlusion, bleeding, and diverticular inflammation. MD's complications are challenging preoperative diagnoses, as manifest with clinical symptoms that overlap with those of other acute non-traumatic abdominal diseases. Thus, in the emergency setting, abdominal computed tomography (CT) represents an essential tool for the correct diagnosis of complicated MD.

Case presentation: We present a case of a preoperative CT diagnosis of perforated Meckel's diverticulitis in a young patient admitted to our Emergency Department complaining of acute abdominal pain.

Conclusions: The case highlights the importance of evaluating Meckel's diverticulum complications among the differential diagnoses of acute non-traumatic abdominal pain and the high sensitivity of CT in assessing their presence in the proper clinical setting.

目的:梅克尔憩室(MD)是一种常见的先天性无症状肠道异常。MD的临床表现约为4. %,表现为并发症,通常为肠闭塞、出血和憩室炎症。MD的并发症是术前诊断的挑战,其临床症状与其他急性非创伤性腹部疾病重叠。因此,在急诊情况下,腹部计算机断层扫描(CT)是正确诊断复杂医学的重要工具。病例介绍:我们报告了一例术前CT诊断为穿孔性梅克尔憩室炎的病例,该病例是一名年轻患者,以急性腹痛入院。结论:该病例强调了评估Meckel憩室并发症在急性非外伤性腹痛鉴别诊断中的重要性,以及CT在适当临床环境下评估其存在的高灵敏度。
{"title":"Preoperative CT diagnosis of perforated Meckel's diverticulitis in a young patient: a case report.","authors":"Michele Gambardella, Michele Smaldone, Francesco Iazzetta, Maria Carmela Corbisiero, Gennaro Graviero, Giuseppe Morelli Coppola","doi":"10.1515/jbcpp-2023-0237","DOIUrl":"10.1515/jbcpp-2023-0237","url":null,"abstract":"<p><strong>Objectives: </strong>Meckel's diverticulum (MD) is a common asymptomatic congenital intestinal anomaly. Clinical manifestations of MD can occur in about 4 % of cases by the presentation of its complications, generally intestinal occlusion, bleeding, and diverticular inflammation. MD's complications are challenging preoperative diagnoses, as manifest with clinical symptoms that overlap with those of other acute non-traumatic abdominal diseases. Thus, in the emergency setting, abdominal computed tomography (CT) represents an essential tool for the correct diagnosis of complicated MD.</p><p><strong>Case presentation: </strong>We present a case of a preoperative CT diagnosis of perforated Meckel's diverticulitis in a young patient admitted to our Emergency Department complaining of acute abdominal pain.</p><p><strong>Conclusions: </strong>The case highlights the importance of evaluating Meckel's diverticulum complications among the differential diagnoses of acute non-traumatic abdominal pain and the high sensitivity of CT in assessing their presence in the proper clinical setting.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"93-97"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138451519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The relationship between the history of PDE5-inhibitors assumption and melanoma: a systematic review. pde5抑制剂假设史与黑色素瘤之间的关系:一项系统综述。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-11-21 eCollection Date: 2023-11-01 DOI: 10.1515/jbcpp-2023-0223
Simone Cilio, Giulia Briatico, Gabriella Brancaccio, Federico Capone, Matteo Ferro, Ciro Imbimbo, Andrea Salonia, Giuseppe Argenziano, Felice Crocetto

Introduction: Phosphodiesterase 5 inhibitors (PDE5-is) are used worldwide as first line therapy for erectile dysfunction (ED). Current literature reported data on the warning association between PDE5-is use and the development of cutaneous melanoma. However, these data are contrasting, thus we aim to summarise evidence regarding this association.

Content: A systematic review of all published articles related to the effects of PDE5-is in the development of cutaneous melanoma was performed. PubMed, EMBASE, and Cochrane library were queried for all the published studies indexed up to the 26th of May 2023. A combination of keywords related to PDE5-is and melanoma were used. Only original studies based on human subjects in the English language were included in the analysis.

Summary and outlook: Of 505 articles identified, only eight original articles were considered for further analysis. Overall, five of the selected articles including 657,984 subjects agrees on an increased risk of developing melanoma in PDE5-is users. On the other hand, three original articles based on data regarding 360,915 subjects, disagree with the previous statement declaring any association between PDE5-i use and melanoma. Current literature still reports contrasting data regarding the association between PDE5-is assumption and increased risk of melanoma, but a possible association is described, bringing attention to higher risk melanoma category of patients. More clinical studies are needed to clarify the impact of PDE5-is in the development and progression of melanoma.

磷酸二酯酶5抑制剂(PDE5-is)在世界范围内被用作治疗勃起功能障碍(ED)的一线药物。目前的文献报道了PDE5-is使用与皮肤黑色素瘤发展之间的警示关联的数据。然而,这些数据是对比的,因此我们的目的是总结有关这种关联的证据。内容:系统回顾了所有已发表的关于PDE5-is在皮肤黑色素瘤发展中的作用的文章。检索PubMed、EMBASE和Cochrane库,检索截至2023年5月26日的所有已发表的研究。结合使用与PDE5-is和黑色素瘤相关的关键词。只有以英语为研究对象的原始研究被纳入分析。总结与展望:在505篇文章中,只有8篇原创文章被考虑进行进一步分析。总的来说,入选文章中有5篇(包括657,984名受试者)同意PDE5-is使用者患黑色素瘤的风险增加。另一方面,基于360,915名受试者数据的三篇原创文章不同意先前关于PDE5-i使用与黑色素瘤之间存在关联的声明。目前的文献仍然报道了关于PDE5-is假设与黑色素瘤风险增加之间关系的对比数据,但描述了一种可能的关联,引起了对高风险黑色素瘤患者类别的关注。需要更多的临床研究来阐明pde5在黑色素瘤发生和发展中的影响。
{"title":"The relationship between the history of PDE5-inhibitors assumption and melanoma: a systematic review.","authors":"Simone Cilio, Giulia Briatico, Gabriella Brancaccio, Federico Capone, Matteo Ferro, Ciro Imbimbo, Andrea Salonia, Giuseppe Argenziano, Felice Crocetto","doi":"10.1515/jbcpp-2023-0223","DOIUrl":"10.1515/jbcpp-2023-0223","url":null,"abstract":"<p><strong>Introduction: </strong>Phosphodiesterase 5 inhibitors (PDE5-is) are used worldwide as first line therapy for erectile dysfunction (ED). Current literature reported data on the warning association between PDE5-is use and the development of cutaneous melanoma. However, these data are contrasting, thus we aim to summarise evidence regarding this association.</p><p><strong>Content: </strong>A systematic review of all published articles related to the effects of PDE5-is in the development of cutaneous melanoma was performed. PubMed, EMBASE, and Cochrane library were queried for all the published studies indexed up to the 26th of May 2023. A combination of keywords related to PDE5-is and melanoma were used. Only original studies based on human subjects in the English language were included in the analysis.</p><p><strong>Summary and outlook: </strong>Of 505 articles identified, only eight original articles were considered for further analysis. Overall, five of the selected articles including 657,984 subjects agrees on an increased risk of developing melanoma in PDE5-is users. On the other hand, three original articles based on data regarding 360,915 subjects, disagree with the previous statement declaring any association between PDE5-i use and melanoma. Current literature still reports contrasting data regarding the association between PDE5-is assumption and increased risk of melanoma, but a possible association is described, bringing attention to higher risk melanoma category of patients. More clinical studies are needed to clarify the impact of PDE5-is in the development and progression of melanoma.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"691-697"},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138047063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of habitual breakfast skipping on information processing capacity, cortical response, and cognitive flexibility among medical collegiate - a cross-sectional study. 习惯性不吃早餐对医学大学生信息处理能力、大脑皮层反应和认知灵活性的影响——一项横断面研究。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-11-14 eCollection Date: 2023-11-01 DOI: 10.1515/jbcpp-2023-0178
Anugraha Jennifer, Krishnan Srinivasan, Jeneth Berlin Raj

Objectives: Breakfast replenishes glucose homeostasis and provides other micro-nutrients for the normal functioning of the body after a long night at night. Habitually skipping breakfast leads not only to metabolic disturbances but also to neurocognitive impairment. Hence, the current study was carried out to study the effect of skipping breakfast on neurocognitive functions.

Methods: A 9-item breakfast questionnaire was distributed online to students for identifying habitual breakfast skippers from non-skippers based on inclusion criteria. Random blood glucose was noted and visual and auditory reaction time, critical flicker fusion frequency, and Stroop test were assessed in both groups to assess cognition.

Results: Forty one habitual breakfast skippers who met the inclusion criteria showed increased visual reaction time, and auditory reaction time indicating cognitive impairment. A significant reduction in the Stroop test was observed among the non-skipper group when compared to the skipper group.

Conclusions: This study suggests that skipping breakfast diminishes neurocognitive functions like problem-solving, planning, judgment, information retention, and reasoning.

目的:早餐补充葡萄糖稳态,并提供其他微量营养素,为身体在漫长的夜晚后的正常功能。习惯性不吃早餐不仅会导致代谢紊乱,还会导致神经认知障碍。因此,本研究旨在研究不吃早餐对神经认知功能的影响。方法:通过网络向学生发放一份包含9个项目的早餐问卷,根据纳入标准识别习惯性不吃早餐者和非不吃早餐者。观察随机血糖,并评估视、听反应时间、临界闪烁融合频率和Stroop测试以评估两组患者的认知能力。结果:41名符合纳入标准的习惯性不吃早餐者表现出视觉反应时间增加,听觉反应时间增加,表明认知障碍。与船长组相比,非船长组的Stroop测试显著降低。结论:这项研究表明,不吃早餐会削弱神经认知功能,如解决问题、计划、判断、信息保留和推理。
{"title":"Effect of habitual breakfast skipping on information processing capacity, cortical response, and cognitive flexibility among medical collegiate - a cross-sectional study.","authors":"Anugraha Jennifer, Krishnan Srinivasan, Jeneth Berlin Raj","doi":"10.1515/jbcpp-2023-0178","DOIUrl":"10.1515/jbcpp-2023-0178","url":null,"abstract":"<p><strong>Objectives: </strong>Breakfast replenishes glucose homeostasis and provides other micro-nutrients for the normal functioning of the body after a long night at night. Habitually skipping breakfast leads not only to metabolic disturbances but also to neurocognitive impairment. Hence, the current study was carried out to study the effect of skipping breakfast on neurocognitive functions.</p><p><strong>Methods: </strong>A 9-item breakfast questionnaire was distributed online to students for identifying habitual breakfast skippers from non-skippers based on inclusion criteria. Random blood glucose was noted and visual and auditory reaction time, critical flicker fusion frequency, and Stroop test were assessed in both groups to assess cognition.</p><p><strong>Results: </strong>Forty one habitual breakfast skippers who met the inclusion criteria showed increased visual reaction time, and auditory reaction time indicating cognitive impairment. A significant reduction in the Stroop test was observed among the non-skipper group when compared to the skipper group.</p><p><strong>Conclusions: </strong>This study suggests that skipping breakfast diminishes neurocognitive functions like problem-solving, planning, judgment, information retention, and reasoning.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"755-759"},"PeriodicalIF":0.0,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89718470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and user acceptability testing of healthy heart mobile application - a tool for cardiovascular risk modification among patients with type 2 diabetes mellitus. 健康心脏移动应用程序的开发和用户可接受性测试-一种在2型糖尿病患者中修改心血管风险的工具。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-11-07 eCollection Date: 2023-11-01 DOI: 10.1515/jbcpp-2023-0073
Prithviraj Erande, Ipseeta Ray Mohanty, Sandeep Rai

Objectives: Cardiovascular disease (CVD) remains the primary cause of mortality in individuals with type 2 diabetes mellitus. Digital health has quickly emerged as a technology with the ability to bridge the gap in cardiovascular disease self-management and revolutionize the way healthcare has traditionally been delivered. However, there is little data on the application of mobile technologies for cardiovascular risk reduction among diabetic patients. The current study has been constructed with this in mind.

Methods: A framework for the development of a healthy heart mobile application for CVD risk stratification and risk management among Type 2 diabetes mellitus patients was finalized after consultation with diabetologists, nutritionists, and scientists. The mobile app has three user cases: Patient login, doctor login, and admin login. A questionnaire was designed and the feedback of patients and Physicians was taken regarding the design, presentation, content, and user-friendliness of the app based on responses obtained on the questionnaire.

Results: The Android version of the healthy heart mobile mobile app was developed for CVD risk stratification and risk management among type 2 diabetes mellitus patients. The dashboard of the mobile app displayed the CVD risk score and category (mild, moderate, high, or very high CVD risk; which was colored coded), health tracker to monitor medication adherence, lipid profile, diabetes control, CVD risk profile and compliance with the WHO recommendations regarding diet, physical activity and addictions, User acceptability and experience were tested for the developed healthy heart mobile app among patients and physicians. The majority of the respondents graded the design, presentation, content, and user-friendliness of the app as either excellent or good.

Conclusions: The mobile app for self-management and CVD risk reduction among diabetic patients was successfully developed. The paper and mobile-based CVD risk calculation and stratification were found to be a match for all the participants. The app was updated based on suggestions from the pilot study and was well-accepted by both patients and physicians.

目的:心血管疾病(CVD)仍然是2型糖尿病患者死亡的主要原因。数字健康已经迅速成为一项技术,能够弥合心血管疾病自我管理方面的差距,并彻底改变传统的医疗保健方式。然而,关于移动技术在降低糖尿病患者心血管风险方面的应用,数据很少。当前的研究就是考虑到这一点而构建的。方法:在与糖尿病学家、营养学家和科学家协商后,最终确定了一个用于2型糖尿病患者心血管疾病风险分层和风险管理的健康心脏移动应用程序的开发框架。该移动应用程序有三个用户案例:患者登录、医生登录和管理员登录。设计了一份问卷,并根据问卷中获得的回复,听取了患者和医生对应用程序的设计、演示、内容和用户友好性的反馈。结果:开发了安卓版健康心脏移动应用程序,用于2型糖尿病患者的心血管疾病风险分层和风险管理。移动应用程序的仪表板显示了心血管疾病风险评分和类别(轻度、中度、高或极高心血管疾病风险;彩色编码)、监测药物依从性的健康跟踪器、脂质状况、糖尿病控制、心血管疾病风险状况以及对世界卫生组织关于饮食、体育活动和成瘾的建议的遵守情况,开发的健康心脏移动应用程序在患者和医生中测试了用户的可接受性和体验。大多数受访者将该应用程序的设计、演示、内容和用户友好性评为优秀或良好。结论:成功开发了用于糖尿病患者自我管理和降低心血管疾病风险的移动应用程序。论文和基于移动的CVD风险计算和分层被发现与所有参与者相匹配。该应用程序是根据试点研究的建议更新的,深受患者和医生的欢迎。
{"title":"Development and user acceptability testing of healthy heart mobile application - a tool for cardiovascular risk modification among patients with type 2 diabetes mellitus.","authors":"Prithviraj Erande, Ipseeta Ray Mohanty, Sandeep Rai","doi":"10.1515/jbcpp-2023-0073","DOIUrl":"10.1515/jbcpp-2023-0073","url":null,"abstract":"<p><strong>Objectives: </strong>Cardiovascular disease (CVD) remains the primary cause of mortality in individuals with type 2 diabetes mellitus. Digital health has quickly emerged as a technology with the ability to bridge the gap in cardiovascular disease self-management and revolutionize the way healthcare has traditionally been delivered. However, there is little data on the application of mobile technologies for cardiovascular risk reduction among diabetic patients. The current study has been constructed with this in mind.</p><p><strong>Methods: </strong>A framework for the development of a healthy heart mobile application for CVD risk stratification and risk management among Type 2 diabetes mellitus patients was finalized after consultation with diabetologists, nutritionists, and scientists. The mobile app has three user cases: Patient login, doctor login, and admin login. A questionnaire was designed and the feedback of patients and Physicians was taken regarding the design, presentation, content, and user-friendliness of the app based on responses obtained on the questionnaire.</p><p><strong>Results: </strong>The Android version of the healthy heart mobile mobile app was developed for CVD risk stratification and risk management among type 2 diabetes mellitus patients. The dashboard of the mobile app displayed the CVD risk score and category (mild, moderate, high, or very high CVD risk; which was colored coded), health tracker to monitor medication adherence, lipid profile, diabetes control, CVD risk profile and compliance with the WHO recommendations regarding diet, physical activity and addictions, User acceptability and experience were tested for the developed healthy heart mobile app among patients and physicians. The majority of the respondents graded the design, presentation, content, and user-friendliness of the app as either excellent or good.</p><p><strong>Conclusions: </strong>The mobile app for self-management and CVD risk reduction among diabetic patients was successfully developed. The paper and mobile-based CVD risk calculation and stratification were found to be a match for all the participants. The app was updated based on suggestions from the pilot study and was well-accepted by both patients and physicians.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"773-790"},"PeriodicalIF":0.0,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71482036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The black swan: a case of central nervous system graft-versus-host disease. 黑天鹅:一例中枢神经系统移植物抗宿主病。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-10-17 eCollection Date: 2023-11-01 DOI: 10.1515/jbcpp-2023-0194
Sara Butera, Rita Tavarozzi, Lucia Brunello, Paolo Rivela, Antonella Sofia, Lorenzo Viero, Michela Salvio, Marco Ladetto, Francesco Zallio

Objectives: Graft-versus-host disease (GVHD) of central nervous system is an atypical and rare manifestation of chronic GVHD, presenting with a heterogeneous spectrum of signs and symptoms. Diagnosis of neurological manifestations of GVHD can be highly challenging and remain associated with dismal prognosis, significant morbidity, and reduced quality of life.

Case presentation: In this report, we describe a 39-year-old woman developing neurological signs and symptoms 8 months after allogeneic HSCT magnetic resonance imaging showed multifocal hyperintense lesions involving the periventricular region and frontal subcortical white matter. There was no laboratory evidence of infective or malignant etiology, and the case was diagnosed as CNS-GVHD. The patient was treated with intravenous methylprednisolone pulse therapy and the clinical conditions gradually improved. After few months, patient symptoms progressed despite the addition of high-dose intravenous immunoglobulin, tacrolimus, and a new course of high dose steroids. To engage targeted therapy, the patient underwent brain biopsy that revealed a loss of myelin fibers, perivascular and diffuse infiltration of T cells, and macrophages associated with reactive gliosis, representing a demyelinating disease. We intensified treatment with cyclophosphamide and subsequently introduced ibrutinib as salvage strategy. Despite a magnetic resonance imaging showing great regression of the demyelinating lesions, patient's conditions deteriorated and she died 16 months after HSCT.

Conclusions: CNS-GVHD is a rare complication of HSCT that is difficult to diagnose. Based on our experience, brain biopsy may represent a useful diagnostic tool when the clinical features of neurological symptoms are ambiguous or in patients without evidence of preceding chronic GVHD.

目的:中枢神经系统移植物抗宿主病(GVHD)是慢性GVHD的一种非典型和罕见的表现,表现为多种不同的体征和症状。GVHD神经系统表现的诊断可能极具挑战性,并且仍与预后不佳、发病率高和生活质量下降有关。病例介绍:在本报告中,我们描述了一名39岁的女性在异基因HSCT磁共振成像显示涉及心室周围区域和额皮质下白质的多灶性高信号病变8个月后出现神经体征和症状。没有感染或恶性病因的实验室证据,该病例被诊断为CNS-GVHD。患者接受静脉注射甲基强的松龙脉冲治疗,临床情况逐渐好转。几个月后,尽管添加了高剂量静脉注射免疫球蛋白、他克莫司和新的高剂量类固醇疗程,患者症状仍有所改善。为了进行靶向治疗,患者接受了脑活检,结果显示髓鞘纤维丢失、血管周围和弥漫性T细胞浸润,以及与反应性胶质增生相关的巨噬细胞,这是一种脱髓鞘疾病。我们加强了环磷酰胺的治疗,随后引入了伊布替尼作为挽救策略。尽管磁共振成像显示脱髓鞘病变明显消退,但患者病情恶化,在HSCT后16个月死亡。结论:CNS-GVHD是HSCT的一种罕见并发症,难以诊断。根据我们的经验,当神经系统症状的临床特征不明确或在没有既往慢性移植物抗宿主病证据的患者中,脑活检可能是一种有用的诊断工具。
{"title":"The black swan: a case of central nervous system graft-versus-host disease.","authors":"Sara Butera, Rita Tavarozzi, Lucia Brunello, Paolo Rivela, Antonella Sofia, Lorenzo Viero, Michela Salvio, Marco Ladetto, Francesco Zallio","doi":"10.1515/jbcpp-2023-0194","DOIUrl":"10.1515/jbcpp-2023-0194","url":null,"abstract":"<p><strong>Objectives: </strong>Graft-versus-host disease (GVHD) of central nervous system is an atypical and rare manifestation of chronic GVHD, presenting with a heterogeneous spectrum of signs and symptoms. Diagnosis of neurological manifestations of GVHD can be highly challenging and remain associated with dismal prognosis, significant morbidity, and reduced quality of life.</p><p><strong>Case presentation: </strong>In this report, we describe a 39-year-old woman developing neurological signs and symptoms 8 months after allogeneic HSCT magnetic resonance imaging showed multifocal hyperintense lesions involving the periventricular region and frontal subcortical white matter. There was no laboratory evidence of infective or malignant etiology, and the case was diagnosed as CNS-GVHD. The patient was treated with intravenous methylprednisolone pulse therapy and the clinical conditions gradually improved. After few months, patient symptoms progressed despite the addition of high-dose intravenous immunoglobulin, tacrolimus, and a new course of high dose steroids. To engage targeted therapy, the patient underwent brain biopsy that revealed a loss of myelin fibers, perivascular and diffuse infiltration of T cells, and macrophages associated with reactive gliosis, representing a demyelinating disease. We intensified treatment with cyclophosphamide and subsequently introduced ibrutinib as salvage strategy. Despite a magnetic resonance imaging showing great regression of the demyelinating lesions, patient's conditions deteriorated and she died 16 months after HSCT.</p><p><strong>Conclusions: </strong>CNS-GVHD is a rare complication of HSCT that is difficult to diagnose. Based on our experience, brain biopsy may represent a useful diagnostic tool when the clinical features of neurological symptoms are ambiguous or in patients without evidence of preceding chronic GVHD.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"805-809"},"PeriodicalIF":0.0,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41235607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
3-Day food record: efficacy in patients with type 2 diabetes mellitus. 3天饮食记录:对2型糖尿病患者的疗效。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-09-13 eCollection Date: 2023-11-01 DOI: 10.1515/jbcpp-2023-0202
Auletta Pasquale, D'Arco Raffaele, Corigliano Gerardo, Conte Marisa, Pagano Silvestre, Genovese Valentina, De Fortuna Umberto, Modestino Michele, Palermi Stefano, De Luca Mariarosaria, Guardasole Vincenzo

Objectives: This study aimed to assess the efficacy of the 3-day food records in monitoring and enhancing dietary habits among patients with type 2 diabetes mellitus.

Methods: A total of 49 patients with type 2 diabetes mellitus were enrolled, with 38 completing the study. Participants were instructed to record their food intake over 3 consecutive days every 2 months. Key anthropometric and glycometabolic parameters, including body weight, abdominal circumference, glycated hemoglobin, and fasting blood sugar, were evaluated at baseline and after 6 months.

Results: The introduction of the 3-day food records led to significant improvements in body weight, abdominal circumference, glycated hemoglobin, and fasting blood sugar. Additionally, there was a notable increase in the percentage of patients adhering to the LARN nutritional recommendations, especially concerning the intake of carbohydrates, simple sugars, proteins, fiber, and water. However, adherence to lipid and saturated fat recommendations remained a challenge.

Conclusions: The 3-day food records emerges as a valuable tool in the dietary management of patients with type 2 diabetes mellitus. By facilitating real-time monitoring and feedback, it holds promise in enhancing patient adherence to nutritional guidelines, thereby improving key health outcomes.

目的:本研究旨在评估3天饮食记录在监测和改善2型糖尿病患者饮食习惯方面的疗效。方法:共纳入49例2型糖尿病患者,其中38例完成研究。参与者被要求每两个月连续三天记录他们的食物摄入量。在基线和6个月后评估关键的人体测量和糖代谢参数,包括体重、腹围、糖化血红蛋白和空腹血糖。结果:3天饮食记录的引入使体重、腹围、糖化血红蛋白和空腹血糖显著改善。此外,遵守LARN营养建议的患者比例显著增加,特别是在碳水化合物、单糖、蛋白质、纤维和水的摄入方面。然而,坚持脂质和饱和脂肪的建议仍然是一个挑战。结论:3天饮食记录是2型糖尿病患者饮食管理的一种有价值的工具。通过促进实时监测和反馈,它有望加强患者对营养指南的遵守,从而改善关键的健康结果。
{"title":"3-Day food record: efficacy in patients with type 2 diabetes mellitus.","authors":"Auletta Pasquale, D'Arco Raffaele, Corigliano Gerardo, Conte Marisa, Pagano Silvestre, Genovese Valentina, De Fortuna Umberto, Modestino Michele, Palermi Stefano, De Luca Mariarosaria, Guardasole Vincenzo","doi":"10.1515/jbcpp-2023-0202","DOIUrl":"10.1515/jbcpp-2023-0202","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to assess the efficacy of the 3-day food records in monitoring and enhancing dietary habits among patients with type 2 diabetes mellitus.</p><p><strong>Methods: </strong>A total of 49 patients with type 2 diabetes mellitus were enrolled, with 38 completing the study. Participants were instructed to record their food intake over 3 consecutive days every 2 months. Key anthropometric and glycometabolic parameters, including body weight, abdominal circumference, glycated hemoglobin, and fasting blood sugar, were evaluated at baseline and after 6 months.</p><p><strong>Results: </strong>The introduction of the 3-day food records led to significant improvements in body weight, abdominal circumference, glycated hemoglobin, and fasting blood sugar. Additionally, there was a notable increase in the percentage of patients adhering to the LARN nutritional recommendations, especially concerning the intake of carbohydrates, simple sugars, proteins, fiber, and water. However, adherence to lipid and saturated fat recommendations remained a challenge.</p><p><strong>Conclusions: </strong>The 3-day food records emerges as a valuable tool in the dietary management of patients with type 2 diabetes mellitus. By facilitating real-time monitoring and feedback, it holds promise in enhancing patient adherence to nutritional guidelines, thereby improving key health outcomes.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"767-771"},"PeriodicalIF":0.0,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10227409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Basic and Clinical Physiology and Pharmacology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1